- Home
- ABEO vs EIC Comparison
ABEO vs EIC Comparison
Compare ABEO & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- EIC
- Stock Information
- Founded
- ABEO 1974
- EIC N/A
- Country
- ABEO United States
- EIC United States
- Employees
- ABEO N/A
- EIC N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- ABEO Health Care
- EIC Finance
- Exchange
- ABEO Nasdaq
- EIC Nasdaq
- Market Cap
- ABEO 289.2M
- EIC 348.9M
- IPO Year
- ABEO 1980
- EIC 2019
- Fundamental
- Price
- ABEO $5.64
- EIC $13.07
- Analyst Decision
- ABEO Strong Buy
- EIC
- Analyst Count
- ABEO 6
- EIC 0
- Target Price
- ABEO $18.17
- EIC N/A
- AVG Volume (30 Days)
- ABEO 783.9K
- EIC 155.9K
- Earning Date
- ABEO 11-13-2025
- EIC 11-13-2025
- Dividend Yield
- ABEO N/A
- EIC 11.94%
- EPS Growth
- ABEO N/A
- EIC N/A
- EPS
- ABEO 0.99
- EIC 0.70
- Revenue
- ABEO $400,000.00
- EIC $55,581,156.00
- Revenue This Year
- ABEO N/A
- EIC $37.84
- Revenue Next Year
- ABEO $324.71
- EIC $23.33
- P/E Ratio
- ABEO $5.70
- EIC $18.78
- Revenue Growth
- ABEO N/A
- EIC 56.39
- 52 Week Low
- ABEO $3.93
- EIC $12.10
- 52 Week High
- ABEO $7.54
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- ABEO 30.38
- EIC 40.60
- Support Level
- ABEO $5.52
- EIC $13.05
- Resistance Level
- ABEO $5.82
- EIC $13.45
- Average True Range (ATR)
- ABEO 0.29
- EIC 0.18
- MACD
- ABEO -0.16
- EIC -0.08
- Stochastic Oscillator
- ABEO 7.84
- EIC 2.30
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.